| Bioactivity | Sodium zirconium cyclosilicate is an orally administered, non-absorbed, novel, inorganic microporous zirconium silicate compound, is a highly selective cation exchanger that selectively removes excess K+ in vivo. Sodium zirconium cyclosilicate can be used in research of chronic kidney disease (CKD)[1][2]. |
| Invitro | Sodium zirconium cyclosilicate (ZS-9) is an inorganic cation exchange crystalline compound that has a high capacity to selectively entrap monovalent cations, specifically excess K+ and ammonium ions. Sodium zirconium cyclosilicate has the exchange capacities for the divalent ions Ca2+ and Mg2+ are below 0.05 mEq/g, and a >25-fold selectivity for K+ over either Ca2+ or Mg2+[1]. |
| In Vivo | Sodium zirconium cyclosilicate (ZS-9; 2-6 g/kg; p.o.; daily, for 5 d) is a recovery in feces of Sprague-Dawley rats and can efficient uptake and removal of potassium ions[2]. Animal Model: |
| Name | Sodium zirconium cyclosilicate |
| CAS | 17141-74-1 |
| Formula | H6O9Si3.2Na.Zr |
| Molar Mass | 371.50 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Stavros F, et, al. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One. 2014 Dec 22;9(12):e114686. [2]. Ash SR, et, al. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int. 2015 Aug;88(2):404-11. |
Sodium zirconium cyclosilicate
CAS: 17141-74-1 F: H6O9Si3.2Na.Zr W: 371.50
Sodium zirconium cyclosilicate is an orally administered, non-absorbed, novel, inorganic microporous zirconium silicate
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.